Back to All Combinations

BRAF V600E + MSS

Intermediate Prognosis
8.00% Prevalence A General
Actionable Target
FDA-approved targeted therapies or strong clinical trial evidence available
Genes Involved
BRAF V600E MSS
Treatment Implications

FIRST-LINE: Encorafenib + Cetuximab + mFOLFOX6 (BREAKWATER, OS 30.3mo). SECOND-LINE+: Encorafenib + Cetuximab (BEACON). Note: MSS BRAF V600E has very poor prognosis without targeted therapy.

Recommended Treatments
Encorafenib + Cetuximab + mFOLFOX6 (first-line)
Encorafenib + Cetuximab (second-line)
Treatments to Avoid
Standard doublet chemotherapy alone
Anti-EGFR monotherapy
Study References

BREAKWATER (NEJM 2025), BEACON (PMID: 33503393)

Key Statistics
8.00%
Prevalence in CRC
Yes
Targetable
Clinical Notes
BRAF V600E + MSS is one of the worst prognostic groups in mCRC. BREAKWATER data now offers hope with targeted first-line therapy. Median OS improved from 15 to 30 months. Test all mCRC for BRAF at diagnosis.
Information

Category: General

Evidence Level: A

Last Updated: Dec 21, 2025

Related Combinations
Medical Disclaimer: This information is for educational purposes only and should not replace professional medical advice. Always consult with your oncologist for personalized treatment decisions based on your specific situation.